PRAX Key Statistics, Chart & Performance
The current stock price of PRAX is 268.8 USD. In the past month the price increased by 50.94%. In the past year, price increased by 283.02%.
PRAX Latest News, Press Relases and Analysis
PRAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About PRAX
Company Profile
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Company Info
PRAXIS PRECISION MEDICINES I
99 High Street, 30th Floor
Boston MASSACHUSETTS 02142 US
CEO: Marcio Souza
Employees: 116
Phone: 16173008460
PRAXIS PRECISION MEDICINES I / PRAX FAQ
What does PRAXIS PRECISION MEDICINES I do?
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Can you provide the latest stock price for PRAXIS PRECISION MEDICINES I?
The current stock price of PRAX is 268.8 USD. The price increased by 0.57% in the last trading session.
Does PRAX stock pay dividends?
PRAX does not pay a dividend.
How is the ChartMill rating for PRAXIS PRECISION MEDICINES I?
PRAX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about PRAXIS PRECISION MEDICINES I (PRAX) stock?
21 analysts have analysed PRAX and the average price target is 297.43 USD. This implies a price increase of 10.65% is expected in the next year compared to the current price of 268.8.
What sector and industry does PRAXIS PRECISION MEDICINES I belong to?
PRAXIS PRECISION MEDICINES I (PRAX) operates in the Health Care sector and the Biotechnology industry.
PRAX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PRAX. When comparing the yearly performance of all stocks, PRAX is one of the better performing stocks in the market, outperforming 99.71% of all stocks.
PRAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRAX. While PRAX has a great health rating, there are worries on its profitability.
PRAX Financial Highlights
Over the last trailing twelve months PRAX reported a non-GAAP Earnings per Share(EPS) of -12.9. The EPS decreased by -25.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.88% | ||
| ROE | -79.49% | ||
| Debt/Equity | 0 |
PRAX Forecast & Estimates
21 analysts have analysed PRAX and the average price target is 297.43 USD. This implies a price increase of 10.65% is expected in the next year compared to the current price of 268.8.
For the next year, analysts expect an EPS growth of -29.57% and a revenue growth -79.37% for PRAX